CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 92 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00688753
NCT00688753Phase 2Completed
CompareCT.gov

A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer

Novartis Pharmaceuticals·interventional·Posted Jun 3, 2008·Updated Sep 2, 2016

In Brief

A Phase 2 clinical trial evaluating RAD001 for Carcinoma and 4 related conditions. Completed, enrolled 92 participants across 19 sites in 6 countries.

Detailed Summary

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma, Adenocarcinoma
CountriesBelgium, France, Germany, Italy, Poland, Spain
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2008
Enrollment StartJul 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.1 years ago

Interventions

RAD001drug